tella, Inc. is a Japan-based company mainly engaged in the provision of techniques and operational knowhow associated with cell medicines, as well as the research and development of regenerative medicine and cell medicine. The Company operates through three business segments. The Cell Medicine segment is engaged in the provision of cancer treatment technology and operational method centered on dendritic cell vaccine therapy. This segment is also engaged in the provision of Services for contract medical institutions, such as cell culture system maintenance support services, management system maintenance support services and disease support services. The Medical Support segment is mainly engaged in the provision of drug development services (CROs) and genetic testing services. The Pharmaceutical segment is engaged in the development of the dendritic cell vaccine for regulatory approval as a product for cancer regenerative medicine.